Akebia Therapeutics vs Ideaya Biosciences
Akebia Therapeutics and Ideaya Biosciences are similar in size: $236m and $219m of revenue in their latest fiscal years. Ideaya Biosciences grew faster (3024.4% against 47.5%). Akebia Therapeutics kept more of each dollar of sales as profit: a net margin of -2.3% against -52.0%.
| Latest fiscal year | Akebia TherapeuticsAKBA, 2025 | Ideaya BiosciencesIDYA, 2025 |
|---|---|---|
| Revenue | $236m | $219m |
| Revenue growth | 47.5% | 3024.4% |
| Net income | −$5.3m | −$114m |
| Operating margin | — | -72.8% |
| Net margin | -2.3% | -52.0% |
| Return on equity | — | -10.9% |
| Free cash flow | $67.7m | −$73.5m |
| Cash | $185m | $113m |
| Total debt | $52.4m | $0 |
| Debt to equity | — | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 194 | 145 |
| Market value | $193m | $3.02bn |
| Price vs our value range | — | — |
| Moat score | 23 (Weak) | — |
| Insider trades, 12 months | 1 buys, 16 sales | 1 buys, 3 sales |